Trial intelligence / Profile preview

Irinotecan + capecitabine with concurrent chemoradiotherapy for unresectable locally advanced gastric cancer

ChiCTR-ONC-13003949Phase 2Completed

Sponsor
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Start
Sep 2014
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of irinotecan and capecitabine in gastric adenocarcinoma, sponsored by Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Primary endpoint: Progression-free survival. Started Sep 2014; status: completed.

02

Drugs

irinotecancapecitabine
03

Conditions

gastric adenocarcinoma

Beyond the preview

Go deeper on ChiCTR-ONC-13003949.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR-ONC-13003949.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call